KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Battistella, M

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. [electronic resource] - The British journal of dermatology Aug 2016 - 325-33 p. digital

Publication Type: Journal Article

1365-2133

10.1111/bjd.14626 doi


Adolescent
Adult
Aged
Antibodies, Monoclonal--pharmacology
Antineoplastic Agents--pharmacology
Cell Line, Tumor
Female
Humans
Ki-1 Antigen--metabolism
Killer Cells, Natural--physiology
Leukocytes, Mononuclear--metabolism
Lymphoma, Large-Cell, Anaplastic--drug therapy
Male
Middle Aged
Receptors, KIR2DL2--antagonists & inhibitors
Skin--metabolism
Skin Neoplasms--drug therapy
Tumor Cells, Cultured
Young Adult